APC201 / Andros Pharma - LARVOL DELTA

A Phase II Study to Investigate the Safety and efficacy of APC201 for the Treatment of Pain Associated with Osteoarthritis of the Knee (ANZCTR) - P2 | N=60 | Completed | Sponsor: Andros Pharmaceuticals Pty Ltd | Not yet recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

A Phase I, Open-Label Study to Evaluate the Safety and Pharmacokinetics of APC201 in Healthy Volunteers (ANZCTR) - P1 | N=10 | Completed | Sponsor: Andros Pharmaceuticals Pty Ltd | Not yet recruiting ➔ Completed | Initiation date: Nov 2023

Trial completion • Trial initiation date • Anesthesia • Immunology • Osteoarthritis • Pain • Rheumatology

[Announcement] The Phase II clinical trial of APC201, a new Chinese drug developed by Jingtiandai subsidiary, for local pain caused by knee osteoarthritis in Australia has begun. [Google translation] (stock.yahoo) - "The Phase II clinical trial of APC201, a new Chinese drug developed on behalf of a subsidiary, for local pain caused by knee osteoarthritis has begun in Australia....This trial is a formal human phase I/II clinical trial study for local pain caused by knee osteoarthritis."

Trial status • CNS Disorders • Osteoarthritis • Pain

Jingtian completed the current increase, the 260 million yuan silver bullet was in place ahead of schedule, and dual strategies promoted the development of APC101 new drugs [Google translation] (stock.yahoo) - "In terms of new drug development, APC201, a new foam drug for the treatment of local pain in osteoarthritis, has recently completed the enrollment of its first subject and has officially launched Phase I/II clinical trials in Australia. The Phase I part will enroll 10 healthy subjects to verify The focus is on safety, and it is expected to be completed before the end of this year; after that, it will directly enter the second phase of clinical trials, with 60 patients expected to be enrolled to confirm the dosage and preliminary efficacy."

Trial status • CNS Disorders • Osteoarthritis • Pain

[Announcement] The Phase I/II clinical trial of APC201, a subsidiary of Jingtiandai, for local pain caused by knee osteoarthritis has begun. [Google translation] (stock.yahoo) - "The Phase I/II clinical trial of APC201, a subsidiary company, for local pain caused by knee osteoarthritis has begun....The Phase I/II clinical trial on local pain caused by osteoarthritis has been approved by the Australian Therapeutic Goods Administration (TGA) for review....The Phase I/II clinical trial will be implemented by the CRO organization and is expected to enroll 70 subjects. The Phase I clinical trial will enroll 10 subjects."

New P1/2 trial • CNS Disorders • Osteoarthritis • Pain